Ephedra: risk of adverse cardiovascular events

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1325, 2002-01, pp. : 21-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thiazolidinedione treatment is not associated with an increased risk of major adverse cardiovascular events

Inpharma, Vol. 1, Iss. 1643, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Verapamil for preventing adverse cardiovascular events

Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Ephedra: much greater risk of adverse reactions than other herbs

Inpharma, Vol. 1, Iss. 1375, 2003-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Lipid Management Strategies for the Prevention of Adverse Cardiovascular Events

Heart Drug, Vol. 2, Iss. 4, 2002-11 ,pp. : 159-161

Karger

Access to resources Recommend Favorite

Common mutations and polymorphisms predicting adverse cardiovascular events: current view

By Visvikis-Siest Sophie Stathopoulou Maria G Ndiaye Ndeye Coumba

Pharmacogenomics, Vol. 13, Iss. 16, 2012-12 ,pp. : 1875-1878

Future Medicine

Access to resources Recommend Favorite